Advertisement

Neurobiologische Grundlagen der Zwangsstörung

  • Fritz Hohagen
Conference paper
Part of the Die Reihe dupbar med communication wird / Series dupbar med communication book series (dmc)

Zusammenfassung

Hirnorganische Faktoren scheinen bei der Pathogenese der Zwangserkrankung eine große Rolle zu spielen, wobei eine funktionelle Störung im Zusammenspiel von Frontalhirn, limbischem System und Basalganglien vorzuliegen scheint. Dem serotonergen System kommt bei der Entstehung von Zwangssymptomen eine große Bedeutung zu. Ein so komplexes Krankheitsbild wie das der Zwangsstörung läßt sich jedoch nicht aus einem Neurotransmittersystem allein erklären, sondern muß als Interaktion psychologischer und biologischer Faktoren verstanden werden.

Genetische Befunde aus Familien- und Zwillingsstudien werden berichtet, klinische Beobachtungen von Zwangssymptomen, die mit verschiedenen neurologischen Erkrankungen einhergehen, werden diskutiert.

Ergebnisse neuropsychologischer und neurochirurgischer sowie PET-Untersuchungen an Patienten mit Zwangsstörungen werden erläutert.

Neurobiological Bases of Obsessive-Compulsive Disorder

Summary

Brain organic factors seem to play an important role in the pathogenesis of obsessive-compulsive disorder (OCD), in which there seems to be a functional disorder in the interaction of frontal brain, limbic system, and basal ganglia. The serotonergic system is of utmost importance in the emergence of obsessive-compulsive symptoms. A syndrome as complex as OCD cannot, however, be explained by neurotransmitter systems alone but has to be regarded as an interaction of psychological and biological factors.

A report of the genetic findings of family and twin studies and a discussion on clinical observations of obsessive-compulsive symptoms in patients with neurological disorders are presented here.

A comment on the results of neuropsychological, neurosurgical, and PET-studies in patients with obsessive-compulsive disorders will also be given.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381PubMedCrossRefGoogle Scholar
  2. Ananth J (1976) Treatment of obsessive compulsive neurosis: pharmacological approach. Psychosomatics 17:180–184PubMedGoogle Scholar
  3. Ananth J, Pecknold J, Van den Steen N (1981) Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 5:257–262PubMedCrossRefGoogle Scholar
  4. Anden NE (1970) Oral L-dopa treatment of parkinsonism. Acta Med Scand 187:247–255PubMedCrossRefGoogle Scholar
  5. Baxter LR, Phelps ME, Mazziotta JC et al. (1987) Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Pschiat 44:211–218CrossRefGoogle Scholar
  6. Bender L (1935) Anatomopathological data on personality. Am J Psychiat 92:325–351Google Scholar
  7. Brickner, RM (1940) A human cortical area producing repetitive phenomena when stimulated. J Neurophysiol 3:128–130Google Scholar
  8. Capstick N, Seldrup J (1977) Obsessional states. A study in the relationship between abnormalities occurring at the time of birth and the subsequent development of obsessional symptoms. Acta Psychiat Scand 56:427–431PubMedCrossRefGoogle Scholar
  9. Charney DS, Goodman WK, Price LH et al. (1988) Serotonin function in obsessive-compulsive disorder. Arch Gen Psychiat 45:177–185PubMedCrossRefGoogle Scholar
  10. Coryell W (1981) Obsessive-compulsive disorder and primary unipolar depression. J Nerv Mental Diseases 169:220–224CrossRefGoogle Scholar
  11. Delini-Stula A, Vassout A (1979) Modulation of dopamine-mediated behavioural responses by antidepressants: effects of single and repeated treatment. Eur J Pharmacol 58:443–451PubMedCrossRefGoogle Scholar
  12. DeSimoni MG, Dal Toso G, Fodritto F et al. (1987) Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411:81–88CrossRefGoogle Scholar
  13. De Voxvrie G van (1968) Anafranil (G34586) in obsessive neurosis. Acta Neurol Belg 68:787–792Google Scholar
  14. Ellinwood EH (1967) Amphetamine psychosis, description of the individuals and the process. J. Nerv Mental Diseases 144:273–283CrossRefGoogle Scholar
  15. Emson PC, Lindvall O (1979) Distribution of putative neurotransmitters in the neocortex. Neuroscience 4:1–30PubMedCrossRefGoogle Scholar
  16. Fernandez CE, Lopez-Ibor JJ (1967) Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso esp Neurol Psiquiat 26:119–147Google Scholar
  17. Flament MF, Rapoport JL, Berg CJ (1985a) Clomipramine treatment of childhood disorder. Arch Gen Psychiat 42:977–983CrossRefGoogle Scholar
  18. Flament MF, Rapoport JL, Berg CJ et al. (1985b) Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiat 42:977–983CrossRefGoogle Scholar
  19. Flament MF, Rapoport JL, Murphy DL et al. (1987) Biochemical Changes during Clomipramin Treatment of Childhood Obsessive-Compulsive Disorder. Arch Gen Psychiat 44:219–225PubMedCrossRefGoogle Scholar
  20. Fontaine R, Chouinard G (1985) Fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiat 9:605–608CrossRefGoogle Scholar
  21. Fontaine R, Chouinard G, Iny L (1985) An open clinical trial of zimelidine in the treatment of obsessive-compulsive disorder. Curr Ther Res 37(2):326–332Google Scholar
  22. Freud S (1894) Die Abwehr-Neuropsychosen. In: Gesammelte Werke, Bd 1. Fischer, Frankfurt/M 1960, S 57Google Scholar
  23. Freud S (1926) Die Frage der Laienanalyse. In: Gesammelte Werke, Bd 14. Fischer, Frankfurt/M 1960, S 207Google Scholar
  24. Fuster JM (1980) The prefrontal cortex: anatomy, physiology and neuropsychology of the frontal lobes. Raven, New YorkGoogle Scholar
  25. Gately PF, Poon SL, Segal DA, Geyer MA (1985) Depletion of brain serotonin by 5, 7-dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats. Psychopharmacology 87:400–405PubMedCrossRefGoogle Scholar
  26. Geisler A, Schou M (1970) Lithium treatment of obsessive-compulsive neurosis: a double-blind therapeutic trial. Nord Psychiat Tidsskr 23:493–495 (in Danish with English abstr)CrossRefGoogle Scholar
  27. Goodman WK, Price LH, Rasmussen SA et al. (1989) Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiat 46:36–44PubMedCrossRefGoogle Scholar
  28. Goodman WK, Price LH, Delgado PL et al. (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiat 47:577–585PubMedCrossRefGoogle Scholar
  29. Guyotat J, Favre-Tissot M, Marie-Gardine M (1968) A clinical trial with a new antidepressant G34586. In: CR Congr Psychiatry and neurology, Dijon. Masson, Paris, pp 717–772Google Scholar
  30. Hervé D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71–83PubMedCrossRefGoogle Scholar
  31. Hesso OC, Thorell LH (1970) Lithium and obsessive-compulsive neurosis: a double-blind crossover clinical therapeutic pilot trial. Nord Psykiat Tidsskr 23:496–499 (in Norwegian; English Abstr)CrossRefGoogle Scholar
  32. Hollander E, De-Caria C, Gully R et al. (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiat Res 36:1–17CrossRefGoogle Scholar
  33. Inouye E (1965) Similar and dissimilar manifestations of obsessive-compulsive neurosis in monozygotic twins. Am J Psychiat 121:1171–1175PubMedGoogle Scholar
  34. Insel TR, Gillin JC, Moore A et al. (1982) Sleep in obsessive-compulsive disorder. Arch Gen Psychiat 93:1372–1377CrossRefGoogle Scholar
  35. Insel TR, Zohar J (1987) Psychopharmacologic approaches to obsessive-compulsive disorder. Psychopharmacology 123:1205–1210Google Scholar
  36. Insel TR, Murphy DL, Cohen RM et al. (1983 a, b) Obsessive compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiat 40:605–612CrossRefGoogle Scholar
  37. Insel TR, Müller EA, Gillin JC et al. (1984) Biological markers in obsessive-compulsive and affective disorders. J Psychiat Res 18, 4:407–423PubMedCrossRefGoogle Scholar
  38. Kahn RS, Westenberg HGM, Jolies J (1984) Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiat Scand 69:259–261PubMedCrossRefGoogle Scholar
  39. Kahn RS, Kalus O, Wetzler S et al. (1990) Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiat Res 33:189–198CrossRefGoogle Scholar
  40. Kettl PA, Marks IM (1986) Neurological factors in obsessive-compulsive disorder: two case reports and a review of the literature. Br J Psychiat 149:315–319CrossRefGoogle Scholar
  41. Khanna S (1988a) Obsessive-compulsive disorder: is there a frontal lobe dysfunction? Biol Psychiat 24:602–613CrossRefGoogle Scholar
  42. Khanna S (1988b) Carbamazepine in obsessive-compulsive disorder. Clin Neuropharmacol 11:478–481CrossRefGoogle Scholar
  43. Koizumi HM (1985) Obsessive-compulsive symptoms following stimulants. Biol Psychiat 20:1332–1333PubMedCrossRefGoogle Scholar
  44. Kupfer DJ, Foster FG, Goble P (1978) The application of EEG sleep for the differential diagnosis of affective disorders. Am J Psychiat 135:69–74PubMedGoogle Scholar
  45. Laplane D, Baulac M, Widlöcher D, Dubois B (1984) Pure psychic akinesia with bilateral lesions of basal ganglia. J Neurol Neurosurg Psychiat 47:377–385PubMedCrossRefGoogle Scholar
  46. Lieberman J (1984) Evidence for a biological hypothesis of obsessive-compulsive disorder. Neuropsychobioloy 11:14–21CrossRefGoogle Scholar
  47. Luxenberg JS, Swedo SE, Flament MF et al. (1988) Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiat 145:1089–1093PubMedGoogle Scholar
  48. March JS, Gutzman LD, Jefferson JW, Greist JH (1989) Serotonin and treatment in obsessive-compulsive disorder. Psychiat Dev 1:1–18CrossRefGoogle Scholar
  49. Marks IM (1986) Fears, phobias and rituals. Oxford Univ Press, New YorkGoogle Scholar
  50. Marks IM, Stern RF, Mawson D (1980) Clomipramine and exposure in vivo for obsessive compulsive rituals. Br J Psychiat 136:1–25CrossRefGoogle Scholar
  51. McKeon J, McGuffin P, Robinson P (1984) Obsessive-compulsive neurosis following head injury: a report of four cases. Br J Psychiat 144:190–192CrossRefGoogle Scholar
  52. Montgomery SA (1980) Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharm Med 1:189–192Google Scholar
  53. Pato MT, Pigott TA, Hill JL et al. (1991) Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiat 148, 1:127–129PubMedGoogle Scholar
  54. Pauls LP, Towbin KE, Leckman JF et al. (1986) Gilles de la Tourette’s syndrome and obsessive-compulsive-disorder. Arch Gen Psychiat 43:1180–1182PubMedCrossRefGoogle Scholar
  55. Perse T (1988) Obsessive-compulsive disorder: a treatment review. J Clin Psychiat 49, 2:48–55Google Scholar
  56. Perse T, Greist JH, Jefferson JW (1987) Fluvoxamine treatment for obsessive-compulsive disorder. Am J Psychiat 144:1543–1548PubMedGoogle Scholar
  57. Prasad A (1984) A double-blind study of imipramine versus zimelidine in treatment of obsessive-compulsive neurosis. Pharmacopsychiatry 17:61–62PubMedCrossRefGoogle Scholar
  58. Price LH, Goodman WK, Charney DS (1987) Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiat 144:1059–1961PubMedGoogle Scholar
  59. Rapoport JL (1988) The neurobiology of obsessive-compulsive disorder. JAMA 260, 19:2888–2890PubMedCrossRefGoogle Scholar
  60. Rapoport JL (1991) Reply to commentaries on “recent advances in obsessive-compulsive disorder”. Neuropsychopharmacology, 5, 1:21–22Google Scholar
  61. Rapoport JL, Elkins R, Langer D et al. (1981) Childhood obsessive-compulsive disorder. Am J Psychiat 138:1545–1554PubMedGoogle Scholar
  62. Rasmussen SA (1984) Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am J Psychiat 141:1283–1285PubMedGoogle Scholar
  63. Riemann D, Gann H, Fleckenstein P et al. (1991) Effect of RS 86 on REM latency in schizophrenia. Psychiat Res 38:89–92CrossRefGoogle Scholar
  64. Rylander G (1969) Clinical and medico-criminological aspects of addictions to central stimulating drugs. In: Sjoquiste E, Tottie M (eds) Abuse of central stimulants. Raven, New York, pp 251–273Google Scholar
  65. Sawle GV, Hymas NF, Lees AJ, Frackowiak RSJ (1991) Obsessional slowness. Functional studies with positron emission tomography. Brain 114:2191–2201PubMedCrossRefGoogle Scholar
  66. Schilder P (1938) The organic background of obsessions and compulsions. Am J Psychiat 94:1397–1414Google Scholar
  67. Schneiders JS (1984) Basal ganglia role in behaviors: importance of sensory gating and its relevance to psychiatry. Biol Psychiat 19:1693–1701Google Scholar
  68. Stern RS, Marks IM, Wright J (1980) Clomipramine: plasma levels, side effects, and outcome in obsessive-compulsive neurosis. Postgrad Med J 56:134–139PubMedGoogle Scholar
  69. Stuss DT, Benson DF (1986) The frontal lobes. Raven, New YorkGoogle Scholar
  70. Stuss DT, Kaplan EF, Benson DF et al. (1982) Evidence for the involvement of orbitalfrontal cortex in memory functions: an interference effect. J Comp Psychol 96:913–925CrossRefGoogle Scholar
  71. Swedo SE, Schapiro MB, Grady CL et al. (1989) Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiat 46:518–523PubMedCrossRefGoogle Scholar
  72. Talairach J, Bancaud J, Geir S et al. (1975) The cingulate gyrus and human behavior. Eletroencephal Clin Neurophysiol 34:415–452Google Scholar
  73. Tarsh M (1978) Severe obsessional illness in dizygotic twins treated by leukotomy. Comp Psychiat 19:165–169CrossRefGoogle Scholar
  74. Thoren P, Asberg M, Cronholm B (1980) Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch Gen Psychiat 37:1281–1285PubMedCrossRefGoogle Scholar
  75. Towey J, Bruder G, Hollander E et al. (1990) Endogenous event-related potentials in obsessive-compulsive disorder. Biol Psychiat 28:92–98PubMedCrossRefGoogle Scholar
  76. Tuke DH (1894) Imperative ideas. Brain 17:179–197CrossRefGoogle Scholar
  77. Turner SM, Jacob RG, Beidel DC (1985) Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 5(4):207–212PubMedCrossRefGoogle Scholar
  78. Volavka J, Neziroglu FA, Yaryura-Tobias J (1985) Clomipramine and imipramine in obsessive-compulsive disorder. Psychiat Res 14:85–93CrossRefGoogle Scholar
  79. Wexberg E (1938) Comments on Dr Schilder’s paper. Am J Psychiat 94:1415–1416Google Scholar
  80. Yamaguchi K, Nabeshima T, Kameyama T (1986) Potentation of phencyclidine-induced dopamine-dependent behaviors in rats after pretreatment with serotonin-depletors. J Pharmacobiodyn 9:479–489PubMedGoogle Scholar
  81. Yaryura-Tobias JS, Bhagavan HN (1977) L-Tryptophan in obsessive compulsive disorders. Am J Psychiat 134:1298–1299PubMedGoogle Scholar
  82. Yaryura-Tobias JA, Neziroglu FA (1983) Obsessive-compulsive disorders. Dekker, New YorkGoogle Scholar
  83. Zohar J, Mueller EA, Insel TR et al. (1987) Serotonergic responsivity in obsessive-compulsive-disorder. Arch Gen Psychiat 44:946–951PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Fritz Hohagen

There are no affiliations available

Personalised recommendations